Acton-based Neuroptix Corp. has been granted a $1 million milestone payment from Merck & Co. Inc. under a previously announced Alzheimer’s Disease diagnostic collaboration.
Begun in late 2006, the collaboration calls for Neuroptix to provide Merck with access to its laser eye scanning technologies, which help detect Alzheimer’s related proteins.
“We are delighted at the progress currently being made in our diagnostic development work with Merck,” said Paul Hartung, president and CEO of Neuroptix. “We are looking forward to continued success as we advance the development of our eye test for early detection of Alzheimer’s disease, for use in clinical diagnostic settings and for monitoring clinical trials of new Alzheimer’s drugs in the pipeline.”
